問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳建銘

Recruiting

List

10Cases

2026-07-26 - 2029-10-29

Phase III

Not yet recruiting
A phase III, double-blind, placebo-controlled, randomized trial was conducted to evaluate the efficacy and safety of ASP3082 combined with mFOLFIRINOX or NALIRIFOX as first-line treatment in participants with KRAS G12D-mutant metastatic pancreatic adenocarcinoma.

  • Condition/Disease

    Metastatic pancreatic adenocarcinoma

  • Test Drug

    "Xinghui" Xingrui Platinum Intravenous Injection 5 mg/mL ASP3082 Haofu Injection 50 mg Anengde Liposome Injection Kefeiyan Injection 10 mg Anticancer Intravenous Concentrate Erenodin Concentrate Injection Fulinya Injection 10 mg/mL Yilinuo Intravenous Infusion Solution Yile Platinum Injection 5 mg/mL

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2025-10-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)

  • Condition/Disease

    Gastrointestinal Neoplasms

  • Test Drug

    IDRX-42 (GSK6042981) Sunitinib

Participate Sites
6Sites

Recruiting6Sites

2025-09-01 - 2027-05-31

Phase I/II

Active
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients with Advanced Gastric and Gastroesophageal Cancer

  • Condition/Disease

    Gastric Cancer Adenocarcinoma Metastatic Gastroesophageal Adenocarcinoma

  • Test Drug

    BDC-4182

Participate Sites
6Sites

Recruiting6Sites

2024-08-01 - 2027-12-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-07-15 - 2029-11-13

Phase II/III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2022-04-01 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-11-01 - 2026-02-23

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2028-09-01

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-09-01 - 2024-12-11

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-09-18 - 2028-09-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB